Cyclerion Therapeutics, Inc. Annual Report: A Plain-English Guide

This guide explains how Cyclerion Therapeutics performed over the past year. I have translated complex financial filings into simple terms to help you decide if this company fits your investment goals.

1. What does the company do?

Cyclerion is a clinical-stage biotech company that researches and develops medicines to stimulate soluble guanylate cyclase (sGC). Because they are in the research phase, they spend heavily on science without selling commercial products.

The company has shifted to a "lean" model. Instead of conducting all research internally, they now focus on licensing their existing technology to other companies to generate cash.

2. Financial performance

Cyclerion does not yet generate profit from drug sales. For the year ending December 31, 2025, their revenue came primarily from licensing fees.

As a "smaller reporting company," they operate with a higher risk profile. They reported an annual loss of about $18.2 million, as the cost of maintaining their research assets and administrative operations currently exceeds their income.

3. Major wins and challenges

The company’s primary focus is its licensing deals, such as the Akebia License Agreement. These partnerships allow other companies to use Cyclerion’s technology in exchange for payments.

A significant milestone occurred in March 2025, when the company raised $8.5 million through a private stock sale. However, the company faces a high "burn rate," where the costs of legal compliance and patent maintenance continue to outpace the cash received from these partnerships.

4. Financial health

Cyclerion is currently in a "cash burn" phase. As of mid-2025, the market value of stock held by outside investors was approximately $5.7 million, with 4.33 million shares outstanding as of March 2026.

Because they lack steady profit, they rely on external funding to remain operational. They hold $4.2 million in cash in liquid accounts. Management projects this capital will fund operations into the second half of 2026, provided no major unexpected costs arise.

5. Key risks

Biotech investing is often high-stakes. Investors should consider these primary risks:

• Cash Shortages: If the company runs out of money, they may issue more shares. This would reduce your ownership percentage and the value of your current shares.
• License Dependencies: Funding relies on partners like Akebia. If these partnerships fail or do not pay out as expected, the company’s primary income source could vanish.
• Nasdaq Compliance: The company must meet minimum stock price requirements to remain listed on the Nasdaq. Failing to do so could lead to delisting, which would impact the liquidity of your shares.

6. Future outlook

Cyclerion is in a transition period focused on managing its patents and existing license agreements. The company is actively working to cut costs and identify new ways to fund operations without issuing more shares.

Investor Takeaway: When deciding whether to invest, focus on the company's ability to extend its cash runway and secure new licensing deals. Because the company is not yet profitable, its value is tied directly to its ability to successfully monetize its intellectual property and avoid further dilution of shareholder value.